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Introduction: This study aimed to compare the expression profiles
of excision repair crosscomplementation group 1 (ERCC1), x-ray
repair crosscomplementation group 1 (XRCC1), and III-tubulin
between patients with primary non-small cell lung cancer (NSCLC)
and those with metastatic lymph nodes and to identify the prognostic
significance of each chemotherapy resistance protein.
Materials: Those who met the inclusion criteria were patients (1)
with NSCLC, (2) with metastatic lymph nodes (N1 or N2), and (3)
who underwent surgical resection followed by platinum-based ad-
juvant chemotherapy. A total of 82 patients were included in the
study. The expression profile of each protein was evaluated by
immunohistochemistry and compared according to tumor location.
Results: The mean age of the patients was 57.5  8.4 years. There
were 30 N1 and 52 N2 patients. ERCC1 expression was upregulated
in 55% and downregulated in 8% of metastatic lymph nodes, when
compared with primary tumors (p  0.05). XRCC1 was also upregu-
lated in 56% and downregulated in 6% (p  0.05). However,
III-tubulin was upregulated in 12% and downregulated in 45% of
patients (p  0.05). III-tubulin expression in metastatic lymph
nodes was greater in patients with adenocarcinoma than other cell
types. Upregulation of ERCC1 in metastatic lymph nodes was a poor
prognostic factor in N1 patients but not in N2 patients.
Conclusions: Significant changes in the expression profile of each
protein were observed in metastatic lymph nodes. The resistance
protein-guided treatment should be performed after integrative in-
terpretation of expression profiles of each protein in both primary
and metastatic sites.
Key Words: Carcinoma, Non-small cell, Thoracic surgical proce-
dures, Chemotherapy, Adjuvant, Drug resistance, Neoplasm.
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Lymph node metastasis is the most important prognosticfactor in resectable non-small cell lung cancer (NSCLC).
Despite complete resection of primary tumor and draining
metastatic lymphatic chains, a significant number of patients
suffered from recurrences at locoregional and distant sites.1–3
Adjuvant chemotherapy has been administered to patients
with advanced NSCLC in an attempt to prevent distant recur-
rence and improve overall survival.4,5 However, the modest
effect of adjuvant chemotherapy on overall survival increased
the need for proper patient selection criteria and a tailored
treatment regimen based on the responsiveness of cancer cells
to chemotherapeutic agents. DNA repair mechanisms have
recently been emphasized because several DNA repair path-
ways had been known to be related to the resistance to
cisplatin-based chemotherapy.6 Excision repair crosscomple-
mentation group 1 (ERCC1) and x-ray repair crosscomple-
mentation group 1 (XRCC1) are proteins involved in the
nucleotide excision repair pathway and base excision repair
pathway, respectively. Several studies have reported that both
proteins are related to resistance to cisplatin-based chemo-
therapy.7–10 The expression level of type III -tubulin is
known to be related to resistance to taxane, which affects the
cancer cell by inhibiting microtubule disassembly.11,12 Recent
clinical trials aimed to improve the efficacy of chemother-
apy by guiding chemotherapy resistance gene expression.13
However, most of the previous studies did not consider
whether the tumor tissue originated from a primary or
metastatic tumor.
The aim of this study was to investigate the expression
profiles of ERCC1, XRCC1, and type III -tubulin in re-
sected primary tumors and metastatic lymph nodes by immu-
nohistochemistry and to identify differences between these
two tumor sites and the prognostic significance of each
expression profile.
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PATIENTS AND METHODS
Patients
Patients who met the inclusion criteria were those (1)
who underwent primary surgical resection due to NSCLC, (2)
who did not receive neoadjuvant chemotherapy, (3) with
nodal metastasis (pathologic stages II and IIIa), (4) who
received platinum-based adjuvant chemotherapy, and (5) who
had a follow-up period of more than 2 years, patients with T4
stage disease were not included in this study. From July 2000
to August 2006, 82 patients fulfilled the above criteria and
were included in the study. The institutional review board of
our hospital approved this study, and patient consent was
waived.
Immunohistochemistry
Primary tumor and paired one metastatic lymph node
were selected for immunohistochemistry. In each case, a
tissue array block was made from paraffin-embedded speci-
mens. Two-millimeter cores were taken from the specimen
(donor blocks) and inserted into new paraffin blocks (tissue
array blocks) using a trephine apparatus (Superbiochips Lab-
oratories, Seoul, Republic of Korea). Immunohistochemical
staining for ERCC1, XRCC1, and III-tubulin was per-
formed at Superbiochips Laboratories (Seoul, Republic of
Korea). Same antigen retrieval method was applied to all
three markers. The tissues were pretreated using a microwave
antigen retrieval procedure (700 W for 15 minutes) in 10 mM
citrate buffer (pH 6.0). After incubation in 3% hydrogen
peroxide for 6 minutes, immunostaining was performed using
an automated immunostainer (Autoimmunostainer 360, lab-
oratory vision, Fremont, CA). The antibodies used were as
follows: anti-ERCC1 (clone 8F1, GeneTex, San Antonio,
TX; dilution 1:100), anti-XRCC1 (clone 33-2-5, Laboratory
vision, Fremont, CA, dilution 1:300), and anti-III-tubulin
(clone SDL3D10, BioGenex, San Ramon, CA, dilution
1:750). A Vectastain Elite ABC kit (Vector laboratories) was
used to visualize III-tubulin immunostaining, and an Ultra-
vision LP kit (Laboratory Vision, Fremont, CA) was used to
visualize XRCC1 and ERCC1. They were then counter-
stained with Mayer’s hematoxylin for 10 seconds. Evaluation
of immunostaining was performed by a pathologist who was
blind to the patients’ clinical information. Nuclear staining
for ERCC1 and XRCC1 was interpreted as positive and
cytoplasmic staining for III-tubulin was interpreted as pos-
itive. The intensity was graded on a scale of 0 to 3. For
ERCC1 and XRCC1, endothelial cells were used as an
internal control and assigned an intensity of 2. The percent-
age of positive tumor cells was also recorded (Figure 1).
Statistical Methods
Continuous variables are expressed as means  SD.
Nominal variables were expressed as numbers and propor-
tions. Wilcoxon signed rank tests were used to compare the
expression profiles of each resistance protein between pri-
mary and metastatic tumors. The effect of each clinical
parameter on the expression level of resistance proteins was
evaluated by one-way analysis of variance or Kruskal-Wallis
test. The Kaplan-Meier method was used to determine overall
and recurrence-free survival. Univariate analysis was per-
formed using a log-rank test. Multivariate analysis was per-
formed using the Cox proportional hazard model. All factors
with a value of p 0.10 by univariate analysis were included
in the multivariate analysis. Statistical significance was ac-
cepted at the p  0.05 level. Statistical analyses were per-
formed using SPSS 13.0 software (SPSS Inc, Chicago, IL).
RESULTS
Patient Demographics
The mean age of the patients was 57.5 8.4 years, and
there were 52 men and 30 women. Lobectomy, bilobectomy,
and pneumonectomy were performed in 61, 10, and 11
patients, respectively. The cell types comprising resected
tumors were adenocarcinoma in 45, squamous cell carcinoma
in 31, and others in six patients. The mean size of the resected
tumors was 3.8  1.5 cm, and there were 16 T1, 58 T2, and
eight T3 tumors. Thirty patients showed N1 metastasis, and
52 patients showed N2 metastasis. Twenty-three patients
(28%) had stage II disease, and 59 patients (72%) had stage
IIIa disease (Table 1). All patients received platinum-based
adjuvant chemotherapy. Cisplatin was used in 46 patients
(56%), and carboplatin was used in 36 patients (44%). The
combined chemotherapeutic agents were taxane in 52 (63%),
vinorelbine in 19 (23%), gemcitabine in seven (9%), and
etoposide in four patients (5%). The mean number of che-
motherapy cycles was 3.9  1.1.
FIGURE 1. Immunohistochemical staining of (A) excision repair crosscomplementation group 1 (ERCC1), (B) x-ray repair
crosscomplementation group 1 (XRCC1), and (C) III-tubulin.
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Differences in Expression Profiles in Primary
Tumors and Metastatic Lymph Nodes
The expression profiles of each resistance protein in
primary tumor and metastatic lymph nodes were compared.
ERCC1 expression was upregulated by 55% in patients with
metastatic lymph nodes, when compared with those with
primary tumors. However, ERCC1 expression was down-
regulated in only 8% of patients (p  0.05; Figure 2). The
pattern of XRCC1 expression was similar to that of ERCC1.
XRCC1 expression was upregulated in 56% of patients and
downregulated in 6% of patients (Figure 3; p  0.05).
However, the expression profile of III-tubulin was different
than those of XRCC1 and ERCC1. III-Tubulin was upregu-
lated in 12% of patients but downregulated in 45% of patients
(Figure 4). III-Tubulin expression was significantly down-
regulated in patients with metastatic lymph nodes in compar-
ison with those with primary tumors (p  0.05).
Correlation with Other Clinical Factors
The impact of clinical factors on the expression level of
each resistance protein was evaluated. Age, gender, cell type,
stage, tumor size, T stage, and N stage were evaluated. The
expression levels of ERCC1 and XRCC1 were not affected
by any clinical factors, regardless of the tumor site (primary
and metastatic; Tables 2 and 3). However, univariate analysis
revealed that III-tubulin expression in metastatic lymph
nodes was influenced by gender, cell type, and N stage.
Multivariate analysis revealed that the cell type of adenocar-
cinoma was the only clinical factor to have a significant effect
on III-tubulin expression in metastatic lymph nodes. Posi-
tive III-tubulin expression was detected in 73% of adeno-
carcinomas, but only 31% of other cell types showed III-
FIGURE 2. A, Changes in excision repair crosscomplemen-
tation group 1 (ERCC1) expression in primary tumors and
metastatic lymph nodes. B, Fifty-five percent of patients
showed upregulation of metastatic lymph nodes, but down-
regulation was found in only 8% of patients.
FIGURE 3. A, Changes in x-ray repair crosscomplementa-
tion group 1 (XRCC1) expression in primary tumors and
metastatic lymph nodes. B, Fifty-six percent of patients
showed upregulation of XRCC1 expression, but only 6% of
patients showed downregulation.
TABLE 1. Clinicopathological Characteristics
Parameters No. of Patients Percentage
Age (yr) 57.5  8.4
Gender
Male 52 63.4
Female 30 36.6
Surgical procedures
Lobectomy 61 74.4
Bilobectomy 10 12.2
Pneumonectomy 11 13.4
Cell types
Adenocarcinoma 45 54.9
Squamous cell carcinoma 31 37.8
Others 6 7.3
Pathological stage
IIA 4 4.9
IIB 19 23.2
IIIA 59 72.0
Overall survival (5 yr) 67.8
Disease free survival (5 yr) 48.4
Median disease free survival (mo) 38.6
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tubulin expression (Table 3). Clinical factors had no effect on
III-tubulin expression in primary tumors.
Survival
The median follow-up period was 28.3 months (3–88
months). Twenty-three patients (28%) died during the fol-
low-up period, and 40 patients (49%) had recurrent lung
cancer. The 3- and 5-year overall survival rates were 77% and
68%, respectively. The 3-year overall survival rate was 78%
in patients with stage II disease and 64% in patients with
stage IIIa disease (p  0.194). The 3- and 5-year recurrence-
free survival rates were 52% and 48%, respectively. The
3-year recurrence-free survival rate was 69% in patients with
stage II disease and 45% in patients with stage IIIa disease
(p  0.056). The expression level itself was not a significant
prognostic factor for overall survival. The upregulation of
ERCC1 expression in metastatic lymph nodes (upregulation)
was a significant risk factor in N1 disease (p  0.024; Figure
5A). However, the prognostic effect of upregulation was not
identified in N2 disease (Figure 5B). The changes in XRCC1
and III-tubulin expression in metastatic lymph nodes did not
affect the overall survival rate. We analyzed the effect of
III-tubulin expression in the subgroup of patients who
FIGURE 4. A, Changes in III-tubulin expression in primary
tumor and metastatic lymph nodes. B, III-Tubulin expres-
sion in metastatic lymph nodes was downregulated in 45%
of patients compared with 12% upregulation.
TABLE 2. The Correlation Between Protein Expression and
Clinical Parameters in Primary Tumor
Positive Expression (>Grade I) Percentage Univariate Multivariate
ERCC1
Age (60 vs. 60 yr old) 27.3:42.9 0.147 —
Gender (male vs. female) 36.7:30.0 0.540 —
Cell type (adenocarcinoma
vs. others)
29.5:40.0 0.330 —
Stage (II vs. III) 40.9:31.6 0.433 —
T stage (T1–2 vs. T3) 36.6:12.5 0.173 —
N stage (N1 vs. N2) 34.5:34.0 0.965 —
Size (5 cm vs. 5 cm) 36.9:21.4 0.268
XRCC1
Age (60 vs. 60 yr old) 74.3:61.4 0.225 —
Gender (male vs. female) 65.3:70.0 0.667 —
Cell type (adenocarcinoma
vs. others)
65.9:68.6 0.802 —
Stage (II vs. III) 81.8:61.4 0.083 0.085
T stage (T1–2 vs. T3) 66.2:75.0 0.615 —
N stage (N1 vs. N2) 79.3:60.0 0.078 0.080
Size (5 cm vs. 5 cm) 70.8:50.0 0.134 —
III-Tubulin
Age (60 vs. 60 yr old) 75.0:69.4 0.580 —
Gender (male vs. female) 70.0:76.7 0.518 —
Cell type (adenocarcinoma
vs. others)
75.6:68.6 0.488 —
Stage (II vs. III) 86.4:67.2 0.087 0.087
T stage (T1–2 vs. T3) 62.5:73.6 0.504 —
N stage (N1 vs. N2) 82.8:66.7 0.121 —
Size (5 cm vs. 5 cm) 73.8:66.7 0.575 —
ERCC1, excision repair crosscomplementation group 1; XRCC1, x-ray repair
crosscomplementation group 1.
TABLE 3. The Correlation Between Protein Expression and
Clinical Parameters in Metastatic Lymph Nodes
Protein Expression
(>Grade I) Percentage Univariate Multivariate
ERCC1
Age (60 vs. 60 yr old) 78.0:64.7 0.200 —
Gender (male vs. female) 69.4:76.9 0.489 —
Cell type (adenocarcinoma
vs. others)
80.0:62.9 0.099 —
Stage (II vs. III) 70.0:72.7 0.816 —
T stage (T1–2 vs. T3) 73.1:62.5 0.527 —
N stage (N1 vs. N2) 66.7:75.0 0.440 —
Size (5 cm vs. 5 cm) 70.0:80.0 0.440 —
XRCC1
Age (60 vs. 60 yr old) 91.7:78.8 0.129 —
Gender (male vs. female) 81.3:95.2 0.129 —
Cell type (adenocarcinoma
vs. others)
91.2:80.0 0.187 —
Stage (II vs. III) 76.5:88.5 0.223 —
T stage (T1–2 vs. T3) 85.2:87.5 0.865 —
N stage (N1 vs. N2) 79.2:88.9 0.275 —
Size (5 cm vs. 5 cm) 88.9:73.3 0.130 —
III-Tubulin
Age (60 vs. 60 yr old) 58.3:45.5 0.285 —
Gender (male vs. female) 42.9:75.0 0.015 0.534
Cell type (adenocarcinoma
vs. others)
73.4:31.4 0.001 0.040
Stage (II vs. III) 35.3:57.7 0.162 —
T stage (T1–2 vs. T3) 55.7:25.0 0.102 —
N stage ( N1 vs. N2) 33.3:62.2 0.022 0.070
Size (5 cm vs. 5 cm) 50.0:52.9 0.830 —
—
ERCC1, excision repair crosscomplementation group 1; XRCC1, x-ray repair
crosscomplementation group 1.
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received taxane-based chemotherapy, but we could not find
any prognostic correlation. We analyzed difference in sur-
vival according to platinum regimen. The 5-year overall and
recurrence-free survival was 63.1% and 46.7% in the patients
with cisplatin regimen and 74.5% and 52.2% in the patients
with carboplatin regimen, and there was no significant dif-
ference according to platinum regimen.
DISCUSSION
Complete excision of the primary tumor and draining of
the lymphatic channel are mainstays of surgical treatment for
NSCLC. In early-stage lung cancer, the cure rate of surgical
resection ranges from 60 to 80%.1,2 However, a significant
proportion of patients with NSCLC are considered to already
have lymphatic or systemic metastasis at the initial presenta-
tion. Because of the early metastatic nature of NSCLC, the
usual mode of treatment failure after surgical resection is
distant recurrence rather than local recurrence.14 Therefore,
the importance of systemic treatment is strongly emphasized
in the treatment of resectable NSCLC. Adjuvant chemother-
apy is being widely used to treat patients who undergo
complete resection. Several studies reported a survival benefit
of adjuvant chemotherapy.4,5 However, only a small portion
of patients benefited from the adjuvant chemotherapy in those
studies. To improve the effectiveness of chemotherapy, pro-
teins resistant to specific chemotherapeutic agents have been
studied. Based on the results of retrospective studies, recent
studies tried to guide the chemotherapy regimen according to
the expression levels of chemotherapy resistance proteins.
Although a long-term result is not yet available, the early
results seem promising.13
Therefore, whether metastatic lesions are more aggres-
sive than primary tumors and alter the expression profiles of
various genes has not yet been determined. However, recent
advances in cancer stem cell theory suggest that cancer stem
cells could be the source of metastasis and drug resistance.
Although cancer stem cells have not yet been detected in lung
cancer, we supposed that a similar feature would be applied
to NSCLC. Considering the findings of previous studies, we
hypothesized that the protein expression profiles between
primary tumor and metastatic site could be different. We
selected ERCC1, XRCC1, and III-tubulin among the resis-
tance-related proteins. ERCC1 and XRCC1, which are in-
cluded in the DNA repair pathway, are related to platinum-
based chemotherapy.7–10 On the other hand, III-tubulin is
not included in the DNA repair pathway, and it is related to
taxane-based chemotherapy.11,12 We compared the expres-
sion profiles of each resistance protein in primary tumors and
metastatic lymph nodes.
The expression profile in this study showed clear dif-
ferences between the resistance proteins. The DNA repair
proteins were upregulated in metastatic lymph nodes,
whereas III-tubulin was downregulated. Whether the meta-
static lesions have the same gene expression profiles as
primary tumors remain a subject of debate. Many studies
reported conflicting results.15 However, recent advances of
cancer stem cell theory raised another issue in chemotherapy
resistance. Cancer stem cells are first found as engrafted cells
when injected into immune-deficient mice, which have the
self-renewing and metastatic potential throughout the entire
cancer cell population.16 This theory can partially explain the
heterogeneity of tumor cell populations and partially explain
the drug resistance in metastatic lesions. Current studies
suggested that cancer stem cells could be a significant cause
of drug resistance.17 Cancer stem cells exhibit little dividing
activity and many cellular mechanisms to evading chemo-
therapy agents. One of the main mechanisms of this resis-
tance is known to be related to the capacity for DNA repair.18
Until recently, the presence of cancer stem cells in lung
cancer was unclear. Furthermore, we cannot say that the
result of our study represents the metastasis of selected clones
of cancer stem cells. However, we could identify that the
metastatic clones of NSCLC in this study showed increased
expression levels of DNA repair proteins.
FIGURE 5. Overall survival according to the level of exci-
sion repair crosscomplementation group 1 (ERCC1) expres-
sion. A, Patients with upregulation of ERCC1 expression in
N1 lymph nodes compared with the primary tumor site
demonstrate significantly poor prognosis in N1 non-small
cell lung cancer (p  0.024). B, It shows survival curves ac-
cording to ERCC1 up- or downregulation in N2 lymph
nodes. However, the change in ERCC1 expression in N2
lymph node did not affect overall survival.
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Generally, it has been known that increased III-tubu-
lin expression is related to high-grade malignancy and cell
type.19 Katsetos et al. analyzed the expression levels of
III-tubulin in lung cancer, and they reported that the expres-
sion level was higher in neuroendocrine tumors but lower in
other types of NSCLC. They also reported that III-tubulin
expression in adenocarcinoma is highly correlated to lymph
node metastasis. However, their report could not show any
statistical significance due to the small number of samples.20
Our study also showed similar results. There was no differ-
ence in III-tubulin expression at the primary tumor site
between adenocarcinoma and other cell types. However, the
III-tubulin expression in metastatic lymph nodes was clearly
higher in adenocarcinoma. The role of III-tubulin in
NSCLC metastasis is not yet known. Thus, further studies are
necessary to determine the role of III-tubulin in lymphatic
metastasis.
Although we tried to identify the prognostic signifi-
cance of three proteins that are known to be related to drug
resistance, the absolute expression level itself was not related
to the prognosis. The only significant risk factor was upregu-
lation of ERCC1 expression in the early stages of metastasis
(N1). We believe that there may be two possible explanations
for this finding. The first possible explanation is that all of the
patients in this study received cisplatin-based chemotherapy.
The prognostic correlation between ERCC1 and cisplatin-
based chemotherapy had already been reported by many
studies.6–9 However, the significance of XRCC1 in cisplatin-
based chemotherapy was not well established until now and
that of III-tubulin remains unclear. Therefore, ERCC1 could
be the only significant risk factor. The second explanation
concerns the limited prognostic value in the early stages of
metastasis. We hypothesized that upregulation in metastatic
lymph nodes shows that more aggressive and chemotherapy-
resistant clones metastasized to adjacent lymph nodes. There-
fore, it could be possible that the prognosis of patients with
N1 disease with no or downregulated expression was good.
However, N2 metastasis represents a higher chance and
burden of systemic metastasis. Although the degree of resis-
tance might be different, the benefit of chemotherapy would
not be great.
In this study, we compared the expression profiles of
resistance proteins between primary tumor and metastatic
lymph nodes in patients who underwent surgical resection
and adjuvant chemotherapy due to NSCLC. DNA repair
proteins, including ERCC1 and XRCC1 were upregulated in
metastatic tumors, when compared with primary tumors;
however, III-tubulin was downregulated in metastatic tu-
mors. Upregulation of ERCC1 in metastatic lymph nodes was
a significant risk factor for overall survival in N1 metastasis
but not in N2 metastasis. Therefore, we believe it is necessary
to decide which site, primary or metastatic, should be the
reference site of protein expression in prospectively designed
clinical trials evaluating chemotherapy resistance.
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